Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK pathway. Its pipeline is built around targeting key signaling nodes, targeting RAS directly, and blocking escape mechanisms that emerge during treatment.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDrug candidates and combination regimens aimed at RAS/MAPK pathway-driven cancers.
In-licensed and acquired assets sourced from third parties to expand the pipeline.
Minority equity investments in early-stage biotechnology companies through Erasca Ventures.
Asiakkaat
Erasca does not currently sell approved products and has no commercial customer base today. Its future customers would be patients with RAS/MAPK-driven cancers, with treatment adoption driven by oncologists, cancer centers, and hospital systems if any candidate is approved. In the near term, the company’s counterparties are research partners, CROs, CMOs, licensors, and potential commercialization partners rather than end-market buyers.
Patients with NRAS-mutated melanoma and other RAS/MAPK-driven solid tumors who would use approved therapies.
Hospitals, cancer centers, and physician groups that would adopt and administer the drugs if approved.
CROs, CMOs, consultants, and scientific advisors that execute trials and manufacturing work.
Biotech and academic partners that provide assets, IP, or commercialization support.
Strategia
Erasca’s strategy is to build a focused precision oncology pipeline around the RAS/MAPK pathway and advance it through biomarker-driven clinical trials. The company also supplements internal discovery with in-licensing, acquisitions, and collaborations, while preserving worldwide development and commercialization rights where possible.
Clinical proof-of-concept is required to create value and support future approvals.
Adaptive and basket/umbrella studies can improve speed and efficiency in heterogeneous cancers.
In-licensing and acquisition broaden the addressable biology without relying only on internal discovery.
A commercial infrastructure will be needed if any candidate is approved, and partnerships may reduce launch burden elsewhere.
Maantiede
Erasca is headquartered in the United States and currently conducts its business primarily through U.S.-based clinical development and corporate operations. Management has said it intends to commercialize in the United States first and potentially in Europe, while seeking partnerships in other regions beyond those markets. Because the company is still pre-commercial, geography mainly affects trial execution, licensing, and future launch planning rather than current sales mix.
Riskit
Erasca is a pre-revenue biotech with a limited operating history, so its value depends on successful clinical development, regulatory approval, and future financing. The company also faces execution risk from trial delays, manufacturing dependence on third parties, cybersecurity exposure, and the possibility that it never generates meaningful product revenue.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Pipeline value depends on proving safety and efficacy in human trials, which is inherently uncertain in oncology.
Kohdistuu: Naporafenib and other RAS/MAPK programs
- Financing riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company has no product sales and expects to fund operations through equity, debt, or collaborations.
Kohdistuu: Ongoing R&D and future commercialization build-out
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Even positive clinical data may not translate into approval, delaying or preventing revenue generation.
Kohdistuu: All product candidates
- Third-party manufacturing and vendor dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on CMOs, CROs, and external service providers for development and supply chain execution.
Kohdistuu: Clinical trials and future product supply
- Cybersecurity and data integrityVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Loss or compromise of clinical trial data could delay regulatory filings and increase recovery costs.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätClinical and preclinical costs are generally expensed as incurred, so trial timing directly affects reported losses.
Vaikutus: Quarterly operating results can swing with trial activity and vendor spend
Employee and director equity awards are a significant non-cash cost for emerging growth biotechs.
Vaikutus: Affects operating expenses and diluted share count
The company holds cash equivalents and marketable securities that must be measured and disclosed appropriately.
Vaikutus: Can affect other income and liquidity presentation
In-licensed or acquired programs may involve upfront payments, contingent consideration, or asset recognition judgments.
Vaikutus: Can affect balance sheet intangibles and future impairment risk
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Processa Pharmaceuticals, Inc.
PCSA · Pharmaceutical Preparations
Cardiff Oncology, Inc.
CRDF · Biological Products, (No Diagnostic Substances)
Ernexa Therapeutics Inc.
ERNAW · Pharmaceutical Preparations
Revolution Medicines, Inc.
RVMD · Biological Products, (No Diagnostic Substances)
Mosaic ImmunoEngineering Inc.
CPMV · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026